Drug Trial Radar · NCT01286935
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
Last checked: Nov 19, 2026Latest source record: Jan 31, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
544
Actual
Start
Aug 2007
Primary completion
Apr 2010
Study completion Aug 2010
Sponsor
- Lead sponsor
- Newron Pharmaceuticals SPAIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the long-term efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations, who are currently receiving a stable dose of levodopa.
Conditions
- Parkinson's Disease
Interventions
SafinamideDrug
SafinamideDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in the dyskinesias rating scale (DRS) during "on" timeTime frame: Up to 104 weeks (from baseline 016 to EOS study 018)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.